STERIS shares have fallen 20.4% over the past six months to $202.39, prompting a reassessment of the stock. Analysts at StockStory cite three reasons to avoid the company: annualized revenue growth of 7.5% over the last two years has decelerated below its five-year trend, adjusted operating margin has remained flat at 23.3% over the trailing twelve months despite revenue gains, and its five-year average return on invested capital stands at a mediocre 5.3%. The stock now trades at 17.9 times forward earnings, which is considered fair but not compelling given the lack of confidence in the business.
STERIS plcRevenue growth deceleration, flat margins, mediocre ROIC, and fair valuation cited as reasons to avoid the stock.